+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Drug Delivery Partnering Terms and Agreements 2015-2022

  • PDF Icon

    Report

  • 900 Pages
  • May 2022
  • Region: Global
  • CurrentPartnering
  • ID: 2314812
The Global Drug Delivery Partnering Terms and Agreements 2015-2022 report provides comprehensive understanding and unprecedented access to the Drug Delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Drug Delivery agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.

The report presents financial deal term values for Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Drug Delivery partnering field; both the leading deal values and most active Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1500 online deal records of actual Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Drug Delivery dealmaking since 2015, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Drug Delivery deals since 2015. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2015. The chapter is organized by specific Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Drug Delivery partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Drug Delivery technologies and products.

Key benefits


Global Drug Delivery Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits:

  • In-depth understanding of Drug Delivery deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Drug Delivery dealmakers since 2015
  • Insight into terms included in a Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope


Global Drug Delivery Partnering Terms and Agreements 2015-2022 is intended to provide the reader with an in-depth understanding and access to Drug Delivery trends and structure of deals entered into by leading companies worldwide.

Drug Delivery Partnering Terms and Agreements includes:

  • Trends in Drug Delivery dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to Drug Delivery contract documents
  • Leading Drug Delivery deals by value since 2015
  • Most active Drug Delivery dealmakers since 2015

In Global Drug Delivery Partnering Terms and Agreements 2015-2022, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Drug Delivery Partnering Terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 1500 Drug Delivery deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in Drug Delivery dealmaking
2.1. Introduction
2.2. Drug Delivery partnering over the years
2.3. Most active Drug Delivery dealmakers
2.4. Drug Delivery partnering by deal type
2.5. Drug Delivery partnering by therapy area
2.6. Deal terms for Drug Delivery partnering
2.6.1 Drug Delivery partnering headline values
2.6.2 Drug Delivery deal upfront payments
2.6.3 Drug Delivery deal milestone payments
2.6.4 Drug Delivery royalty rates
Chapter 3 - Leading Drug Delivery deals
3.1. Introduction
3.2. Top Drug Delivery deals by value
Chapter 4 - Most active Drug Delivery dealmakers
4.1. Introduction
4.2. Most active Drug Delivery dealmakers
4.3. Most active Drug Delivery partnering company profiles
Chapter 5 - Drug Delivery contracts dealmaking directory
5.1. Introduction
5.2. Drug Delivery contracts dealmaking directory
Chapter 6 - Drug Delivery dealmaking by technology type
Appendices
Appendix 1 - Drug Delivery deals by company A-Z
Appendix 2 - Drug Delivery deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
Appendix 3 - Drug Delivery deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty
Appendix 4 - Drug Delivery deals by therapy area
Appendix 5 - Deal type definitions
Appendix 6 - Further reading on dealmaking
Table of figures
Figure 1: Drug Delivery partnering since 2015
Figure 2: Active Drug Delivery dealmaking activity since 2015
Figure 3: Drug Delivery partnering by deal type since 2015
Figure 4: Drug Delivery partnering by disease type since 2015
Figure 5: Drug Delivery deals with a headline value
Figure 6: Drug Delivery deals with an upfront value
Figure 7: Drug Delivery deals with a milestone value
Figure 8: Drug Delivery deals with a royalty rate value
Figure 9: Top Drug Delivery deals by value since 2015
Figure 10: Most active Drug Delivery dealmakers since 2015

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Delta 9 Cannabis
  • Korea Advanced Institute of Science and Technology
  • STADA Arzneimittel
  • TFB & Associates
  • Imbed Bio
  • Sesen Bio
  • Motif Bio
  • Avior Bio
  • Tetra Bio-Pharma
  • Helix BioPharma
  • Carna BioSciences
  • AMPEL BioSolutions
  • Leads Biolabs
  • Orbit Biomedical
  • Proxy Biomedical
  • Dance Biopharm
  • NEMUS Bioscience
  • Artes Biotechnology
  • Tamir Biotechnology
  • Juyou Biotechnology
  • Small Business Innovation Research
  • Auxly Cannabis Group
  • North Carolina State University
  • Magle Chemoswed
  • LatAm Clinical Trials
  • Eve & Co
  • Aceto Corporation
  • Green Cross LabCell
  • Nitto Denko
  • Kwang Dong Pharmaceutical
  • Rapid Dose Therapeutics
  • Fidia Farmaceutici
  • Apsen Farmacutica
  • Grupo Ferrer
  • Altus Formulation
  • Aspen Global
  • Eitan Group
  • Clear Guide Medical
  • Evero Health
  • World Health Organization
  • Bayer Healthcare

Methodology

  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...